Angle PLC - liquid biopsy company - Says Milan, Italy-based cancer research institute Fondazione IRCCS Istituto Nazionale dei Tumori has published results of new work undertaken in triple negative breast cancer patients. Researchers used Angle's Parsortix system to isolate circulating tumour cells in patients with recurrent disease and analysed these concurrently with circulating tumour DNA in the blood.
Angle says the study demonstrates how analysis of CTCs harvested by the Parsortix system, as a liquid biopsy, have significant potential for non-invasive, real-time monitoring of cancer patients, giving insight into "druggable targets" for next line therapy at disease recurrence.
Chief Executive Officer Andrew Newland says: "The use of the Parsortix system in uncovering potential new therapeutic targets through its ability to harvest mesenchymal as well as epithelial CTCs for analysis showcases further evidence of the advantages of using the Parsortix system over antibody-based CTC systems. ANGLE's ability to provide this actionable information could help patients who have limited treatment options and should prove highly attractive to drug developers looking for new approaches for hard-to-treat cancers, such as TNBC.
"Harnessing these unique capabilities in our clinical services laboratories is allowing ANGLE to accelerate the commercial deployment of the Parsortix system by offering services to pharmaceutical and biotech customers for use in cancer drug clinical trials, a market where we are already gaining traction."
Current stock price: 111.40 pence
Year-to-date change: more than double
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Angle (AGL)